medigraphic.com

2020, Number 2

<< Back Next >>

Rev Cuba Endoc 2020; 31 (2)

Generalities of the treatment of diabetic macular edema and the use of statins

Hernández RJ, Redondo PLR

Language: Spanish
References: 58
Page: 1-20
PDF size: 397.06 Kb.


ABSTRACT

Introduction: Any form of diabetic retinopathy can be accompanied by the presence of diabetic macular edema. The use of statins in patients with diabetes mellitus and diabetic macular edema has been suggested as a therapeutic measure.
Objectives: To describe, in a general way, the treatment of diabetic macular edema and, particularly, some outcomes obtained with the use of statins.
Methods: A relevant literature search on the subject was carried out in the first half of 2019. Review and research articles published in the last ten years were assessed, taken from different databases, such as PubMed, Cochrane, SciELO, as well as from web pages, written in Spanish, Portuguese or English. Pubmed, Google and Google Scholar were used as engines for searching scientific information. The following keywords were used: diabetes mellitus, tratamiento [treatment], estatinas [statins], and edema macular diabetic [diabetic macular edema]. Articles that did not meet the objectives of the present work were excluded, which allowed the study of 87 articles, of which 57 were referenced.
Conclusions: Strict glycemic control and confronting modifiable risk factors in patients with diabetes mellitus represents the most important measure to avoid and reduce the appearance and progression of diabetic macular edema. When established, appropriate or specific treatment should be used. The use of statins could be an important complement for the prevention and treatment of diabetic macular edema.


REFERENCES

  1. Landrove O, Morejón A, Venero S, Suárez R, Almaguer M, Pallarols E, et al. Enfermedades no transmisibles: factores de riesgo y acciones para su prevención y control en Cuba. Rev Panam Salud Pública. 2018;42:e23. DOI: 10.26633/RPSP.2018.23

  2. IDF. Diabetes atlas. 9th edition; 2019. [acceso: 11/10/2020]. Disponible en: Disponible en: https://www.diabetesatlas.org/en/sections/individual-social-and-economic-impact.html

  3. WHO. Informe mundial sobre la Diabetes. Ginebra: World Health Organization; Orientation Summary. 2016 [acceso: 29/11/2018]. Disponible en: Disponible en: http://www.who.int/diabetes/global-report/es/

  4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. The Lancet (London). 2016;387(10027):1513-30.

  5. Rivas EM, Zerquera G, Hernández C, Vicente B. Manejo práctico del paciente con diabetes mellitus en la atención primaria de salud. Revista Finlay. 2017;7(1):104-25.

  6. Mora E. Estado actual de la diabetes mellitus en el mundo. Acta Méd. Costarric. 2014;56(2):44-6.

  7. Cuba. Ministerio de Salud Pública. Anuario Estadístico de Salud. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2017. La Habana; 2018. [acceso: 04/12/2018]. Disponible en: Disponible en: http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Español-2017-ed-2018.pdf

  8. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal 2016; 92(1084):63-9.

  9. World Health Organization. Diabetes. Datos y cifras. 2018. [acceso: 29/11/2018]. Disponible en: Disponible en: http://www.who.int/es/news-room/fact-sheets/detail/diabetes

  10. Romero P, Baget M, Martín J, Méndez I, Salvat M. Epidemiología del edema macular. Annals d'oftalmologia: Òrgan de les Societats d'Oftalmologia de Catalunya, Valencia i Balears. 2016;24(4):160-73.

  11. Díaz O, Orlandi N. Manual para el diagnóstico y tratamiento del paciente diabético a nivel primario de salud. La Habana: Editorial de Ciencias Médicas. 2016 [acceso: 01/10/2020]. Disponible en: Disponible en: http://articulos.sld.cu/ecimed/tag/diabetes-mellitusdiagnostico/

  12. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2018. Diabetes Care. 2018;41(Suppl 1):S73-S85.

  13. American Diabetes Association. Glycemic targets: standards of medical care in diabetes - 2018. Diabetes Care. 2018;41(Suppl 1):S55-S64.

  14. Covarrubias T, Delgado I, Rojas D, Coria M. Tamizaje en el diagnóstico y prevalencia de retinopatía diabética en atención primaria. Rev. Méd. Chile. 2017;145(5):564-71.

  15. Pérez ME, Redondo LR, Maciques JE. Our experience in the comprehensive approach to prevention and control of diabetic retinopathy. Revista Cubana de Endocrinología. 2017;28(2):1-4.

  16. Andrade DS, Valencia D, Padilla EA, Quintero JD, Delgado V, Solórzano CA, et al. Caracterización clínica de la retinopatía en el paciente diabético tipo II en institución de salud primer nivel. Pereira 2018. Cuaderno de Investigaciones-Semilleros Andina. 2018;11(11):98-104.

  17. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007; 2007:95103. DOI: 10.1155/2007/95103

  18. Prieto J, Dávila JA, Fierro VA, Flores FA, García A, Hernández F, et al. Estatinas. Lux Médica. 2018;10(29):31-9.

  19. Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412-8.

  20. Das A, McGuire PG, Rangasamy S. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015;122(7):1375-94.

  21. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-82.

  22. Duran C. Sección Retina, Vitreo y Uveitis. Papel de la vitrectomía en el edema macular diabético. Qvisión.es; 2017 [acceso: 21/04/2020]. Disponible en: Disponible en: https://www.qvision.es/blogs/carlos-duran/2017/05/21/papel-de-la-vitrectomia-en-el-edema-macular-diabetico/

  23. Bourne RA, Stevens GA, White RA. Causes of vision loss worldwide, 1990-2010: A systematic analysis. The Lancet Global Health. 2013 [acceso: 07/12/2018];1(6):e339-e349. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S2214109X1370113X

  24. Beltrán RI, Hernández R, Pérez ME, Dyce BL. Utilidad de la tomografía de coherencia óptica para la caracterización y clasificación del edema macular diabético. Rev Haban Cienc Méd. 2018;17(5):692-704.

  25. Cavan D, Makaroff L, da Rocha J, Sylvanowicz M, Ackland P, Conlon J, et al. The Diabetic Retinopathy Barometer Study: Global perspectives on access to and experiences of diabetic retinopathy screening and treatment. Diabetes Research and Clinical Practice. 2017 [acceso: 07/12/2018]; 129:16-24. Disponible en: Disponible en: https://reader.elsevier.com/reader/sd/pii/S0168822717304370?token=435044A3955CB36655CA7A703A49FB668E89AF91FF7891449B56D0A105F0BC6BA3FC8FAC2F56AF11DB0E4A38C2B9FAA2

  26. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-fiveyear incidence of macular edema in persons with type 1 diabetes. Ophthalmology.2009;116(3):497-503.

  27. Romero P, Baget M, Fernández J, Plana N, Soler N, Méndez I, et al. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of type 1diabetes patients. Diabetes Res Clin Pract. 2011;94(1):126-32.

  28. Ortiz R, González CP, Hernández F, Ancona I, Betesh I, Méndez N, et al. Recomendaciones para el uso de ranibizumab en edema macular diabético en el IMSS. Revista Médica del Instituto Mexicano del Seguro Social. 2018;55(6):758-67.

  29. Das T, Aurora A, Chhablani J, Giridhar A, Kumar A, Raman R, et al. Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian Journal of Ophthalmology. 2016;64(1):14-25.

  30. Jorge EC, Jorge EN, Botelho M, Farat JG, Virgili G, El Dib R. Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews. 2018 [acceso: 26/11/2018]. Disponible en: Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010859.pub2/abstract

  31. Thomas BJ, Shienbaum G, Boyer DS, Flynn HW. Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Can J Ophthalmol. 2013;48(1):22-30.

  32. Vila I, Ramos M, Pérez EL, Ruiz M, Pereira E, Padilla González. Intravítrea de bevacizumab vs. bevacizumab y triamcinolona para el edema macular diabético Revista Cubana de Oftalmología. 2016;29(1):16-25.

  33. IRIDEX. Why 577 nm Yellow? Clinical benefits of 577 nm yellow laser in thetreatment of ocular disorders. Montain View: IRIDEX Corporation. 2009 [acceso: 05/02/2019]. Disponible en: Disponible en: http://www.iridex.com/portals/0/lasers/Why-577-nm.pdf

  34. Ramos M, Paulino G, Rafael M, Pupo G, Cerón MI, Hernández A, et al. IRIDEX IQ 577 nm micropulse laser. Revista Cubana de Oftalmología. 2018;31(1):112-22.

  35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.

  36. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012; 119(10):2125-32.

  37. Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek B, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes care, 2017; 40(3):412-18.

  38. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database of Systematic Reviews. 2018 [acceso: 26/11/2018]. Disponible en: Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub5/abstract

  39. Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608-22.

  40. Patel AK, Gentile R. Surgical Treatment of Diabetic Macular Edema. Ret Phys. 2013;10:16-23.

  41. Staurenghi G, Ye L, Magee MH, Danis RP, Wurzelmann J, Adamson P, et al. Darapladib, a Lipoprotein-Associated Phospholipase A 2 Inhibitor, in Diabetic Macular Edema. Ophthalmology. 2015;122(5):990-6.

  42. The STABILITY Investigators. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. N Engl J Med. 2014;370(18):1702-11.

  43. Mazón P. Del concepto de estatinas de alta potencia a los efectos extra lipídicos de las estatinas. Revista Española de Cardiología. 2015;15 (Suppl 1):22-7.

  44. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Current Opinion in Lipidology. 2011;22(3):165-70.

  45. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des. 2009; 15(5):479-89.

  46. VIDAL Vademecum Drug Information Systems. VMP id: 198-2018; 2018. [actualización: 18/10/2018; acceso: 26/11/2018]. Disponible en: Disponible en: https://latam.vidal-consult.com/html_docs/hp/HTML_VMP/vmp_198.html

  47. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6-year follow-up study of the METSIM cohort. Diabetologia. 2015;58(5):1109-17.

  48. Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults. J Gen Intern Med. 2015;30(11):1599-610.

  49. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye. 2002;16(6):689-93.

  50. Idiculla J, Nithyanandam S, Joseph M, Mohan A, Vasu U, Sadiq M. Serum lipids and diabetic retinopathy: A cross-sectional study. Indian J Endocrinol Metab. 2012;16(Suppl 2):S492-S494.

  51. Panagiotoglou TD, Ganotakis ES, Kymionis GD, Moschandreas JA, Fanti GN, Charisis SK, et al. Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol. Ophthalmic Surg Lasers Imaging. 2010;41(3):316-22.

  52. Sen K, Misraa A, Kumar A, Mohan R. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Research and Clinical Practice. 2002;56(1):1-11.

  53. Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014;2(11):894-900.

  54. Gupta A, Gupta V, Thapara S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. American Journal of Ophthalmology. 2004;137(4):675-88.

  55. Chung YR, Park SW, Choi SY, Kim SW, Moon KY, Kim JH, et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovascular Diabetology. 2017 [acceso: 19/12/2018]; 16(1). Disponible en: Disponible en: https://cardiab.biomedcentral.com/articles/10.1186/s12933-016-0486-2

  56. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Lawrence A, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiology. 2017; 2(4):370-80.

  57. Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: a systematic review and meta-analysis. Ophthalmology. 2015;122(9):1820-27.

  58. Al-Janabi A, Lightman S, Tomkins O. Statins in retinal disease. Eye. 2018;32(1):981-91.




2020     |     www.medigraphic.com